Call us 24/7

Clinical trials

Filters

25 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to assess the efficacy and safety of pembrolizumab vsersus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to test study treatments that combine an investigational drug (tucatinib, which is also known as ONT-380) (the “study drug”) with two approved drugs (capecitabine and trastuzumab) in participants with advanced breast cancer to find out what effects, good or bad, it may have on the participants and their disease.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 3 multi-center, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post-menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

In phase 2, the selected combined dose level of AGEN2034 and AGEN1884, established in part A, will be administered for a maximum of two years or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study drugs or withdrawal from the trial occurs. Cancer Treatment Centers of America® (CTCA) is participating in phase 2, part B: Cervical.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this trial is to study the effects of the trūFreeze® Spray Cryotherapy System in subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least three lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.